Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Decreases By 18.0%

AngioDynamics, Inc. (NASDAQ:ANGO) saw a significant drop in short interest in the month of March. As of March 13th, there was short interest totaling 1,784,550 shares, a drop of 18.0% from the February 26th total of 2,176,310 shares. Approximately 4.6% of the shares of the company are short sold. Based on an average daily trading volume, of 282,420 shares, the days-to-cover ratio is currently 6.3 days.

AngioDynamics Stock Performance

Shares of NASDAQ ANGO opened at $10.90 on Monday. The stock has a market cap of $449.30 million, a PE ratio of -16.27 and a beta of 0.48. AngioDynamics has a 12-month low of $8.36 and a 12-month high of $13.99. The company has a 50-day moving average of $10.80 and a 200 day moving average of $11.54.

Institutional Investors Weigh In On AngioDynamics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Alaska Department of Revenue acquired a new position in AngioDynamics during the third quarter worth $25,000. Farther Finance Advisors LLC increased its stake in shares of AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 1,199 shares during the last quarter. Washington Trust Advisors Inc. acquired a new stake in shares of AngioDynamics in the 3rd quarter worth $27,000. Kemnay Advisory Services Inc. purchased a new position in shares of AngioDynamics during the 4th quarter worth $27,000. Finally, State of Wyoming acquired a new position in shares of AngioDynamics during the 2nd quarter valued at about $31,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Zacks Research upgraded shares of AngioDynamics from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 9th. Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a research report on Sunday, December 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $19.33.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.